About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 27 results
Filters: Author is Pasquini, Marcelo C  [Clear All Filters]
2022
A. Dispenzieri, Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., Vesole, D. H., Stadtmauer, E., and Murray, D., Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)., Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial., Transplant Cell Ther, 2022.
S. A. Holstein, Asimakopoulos, F., Azab, A. Kareem, Bianchi, G., Bhutani, M., Crews, L. A., Cupedo, T., Giles, H., Gooding, S., Hillengass, J., John, L., Kaiser, S., Lee, L., Maclachlan, K., Pasquini, M. C., Pichiorri, F., Shah, N., Shokeen, M., Shy, B. R., Smith, E. L., Verona, R., Usmani, S. Z., and McCarthy, P. L., Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma., Transplant Cell Ther, vol. 28, no. 8, pp. 446-454, 2022.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies., J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
A. D'Souza, Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., and Flynn, K. E., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma., Am J Hematol, 2022.
P. G. Richardson, Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., Orlowski, R. Z., Anderson, L. D., Zonder, J. A., Milner, C. P., Gasparetto, C., Agha, M. E., Khan, A. M., Hurd, D. D., Gowin, K., Kamble, R. T., Jagannath, S., Nathwani, N., Alsina, M., R Cornell, F., Hashmi, H., Campagnaro, E. L., Andreescu, A. C., Gentile, T., Liedtke, M., Godby, K. N., Cohen, A. D., Openshaw, T. H., Pasquini, M. C., Giralt, S. A., Kaufman, J. L., Yee, A. J., Scott, E., Torka, P., Foley, A., Fulciniti, M., Hebert, K., Samur, M. K., Masone, K., Maglio, M. E., Zeytoonjian, A. A., Nadeem, O., Schlossman, R. L., Laubach, J. P., Paba-Prada, C., Ghobrial, I. M., Perrot, A., Moreau, P., Avet-Loiseau, H., Attal, M., Anderson, K. C., and Munshi, N. C., Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma., N Engl J Med, vol. 387, no. 2, pp. 132-147, 2022.
2021
S. A. Holstein, Bahlis, N., P Bergsagel, L., Bhutani, M., Bolli, N., Brownstein, C., Demolis, P., Foureau, D., Gay, F., Ghobrial, I. M., Gormley, N., Hillengass, J., Kaiser, M., Maus, M. V., J Melenhorst, J., Merz, M., Dwyer, M. O., Paiva, B., Pasquini, M. C., Shah, N., Wong, S. W., Usmani, S. Z., and McCarthy, P. L., The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma., Transplant Cell Ther, vol. 27, no. 10, pp. 807-816, 2021.
L. W. Dillon, Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Warlick, E. D., Pasquini, M. C., Scott, B. L., Horwitz, M. E., H Deeg, J., and Hourigan, C. S., Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome., JCO Precis Oncol, vol. 5, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial., Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
2020
C. S. Hourigan, Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., H Deeg, J., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Scott, B. L., Warlick, E. D., Pasquini, M. C., and Horwitz, M. E., Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease., J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
L. J. Costa, Iacobelli, S., Pasquini, M. C., Modi, R., Giaccone, L., Blade, J., Schonland, S., Evangelista, A., Perez-Simon, J. A., Hari, P., Brown, E. E., Giralt, S. A., Patriarca, F., Stadtmauer, E. A., Rosinol, L., Krishnan, A. Y., Gahrton, G., and Bruno, B., Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation., Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.
S. A. Holstein, Howard, A., Avigan, D., Bhutani, M., Cohen, A. D., Costa, L. J., Dhodapkar, M. V., Gay, F., Gormley, N., Green, D. J., Hillengass, J., Korde, N., Li, Z., Mailankody, S., Neri, P., Parekh, S., Pasquini, M. C., Puig, N., G Roodman, D., Samur, M. Kemal, Shah, N., Shah, U. A., Shi, Q., Spencer, A., Suman, V. J., Usmani, S. Z., and McCarthy, P. L., Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 10, pp. e247-e255, 2020.
S. A. Holstein, Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L., and McCarthy, P. L., Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 26, no. 1, pp. e7-e15, 2020.
2019
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial., J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
S. A. Holstein, J Ye, C., Howard, A., Bhutani, M., Gormley, N., Hahn, T., Hillengass, J., Krishnan, A., C Landgren, O., Munshi, N. C., Oliva, S., Owen, R. G., Pasquini, M. C., Puig, N., Weinhold, N., Weisel, K., and McCarthy, P. L., Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling., Biol Blood Marrow Transplant, vol. 25, no. 3, pp. e89-e97, 2019.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with , Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
2012
C. A. Keever-Taylor, Devine, S. M., Soiffer, R. J., Mendizabal, A., Carter, S., Pasquini, M. C., Hari, P. N., Stein, A., Lazarus, H. M., Linker, C., Goldstein, S. C., Stadtmauer, E. A., and O'Reilly, R. J., Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303., Biol Blood Marrow Transplant, vol. 18, no. 5, pp. 690-7, 2012.
M. C. Pasquini, Devine, S., Mendizabal, A., Baden, L. R., Wingard, J. R., Lazarus, H. M., Appelbaum, F. R., Keever-Taylor, C. A., Horowitz, M. M., Carter, S., O'Reilly, R. J., and Soiffer, R. J., Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl, J Clin Oncol, vol. 30, no. 26, pp. 3194-201, 2012.
P. L. McCarthy, Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. Scott, van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., and Linker, C., Lenalidomide after stem-cell transplantation for multiple myeloma., N Engl J Med, vol. 366, no. 19, pp. 1770-81, 2012.